Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: Results of phase I study.

WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.

[Dendritic cell-based therapeutic vaccination for acute myeloid leukemia]

Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo

Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells

[Roles of Newcastle disease virus in human acute monocytic leukemia in vitro and in vivo]

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms‘ tumor 1 antigen-targeted dendritic cell vaccination

Immunotherapy of acute myeloid leukemia: current approaches

Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response